Journal of Clinical Oncology
Articles in this Issue
Tracking incidence and prognosis of lung cancer seen in kidney transplant recipients: A retrospective study.
e23357 Background: The incidence of malignancy in solid organ transplant recipients tends to be higher than in the general population. Malignancy is the t...
Impact of treatment patterns on clinical outcomes in patients of advanced pancreatic cancer treated with chemotherapy: A large-scale data analysis from real world practice.
e16367 Background: Fewer treatment choices are available for advanced pancreatic cancer (APC). Nab-paclitaxel is one the most important drugs and has been...
The studies industry neglects: Characteristics of cancer clinical trials conducted by federal versus industry sponsors.
11095 Background: A defining feature of federally sponsored cancer clinical trials is their mandate to examine clinical research questions not routinely a...
Nimotuzumab with chemoradiotherapy for newly diagnosed, high-risk, locally advanced squamous cervical cancer (CC11): A prospective single-arm phase II study.
5521 Background: Cervical cancer ranks as the fourth most common cancer, with 32% of cases being locally advanced (stage IIB-IVA, LACC). The standard trea...
RELATIVITY-020: Intracranial (IC) activity of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with PD-(L)1 refractory melanoma with melanoma brain metastases (MBM).
9525 Background: NIVO + RELA is an anti-PD-1 + anti-LAG3 combination approved for the treatment of pts with advanced melanoma, but data on activity in pts...
Choosing oncology: A cross-sectional study of Caribbean medical students’ fourth-year elective rotation preferences.
e21035 Background: The rising global burden of cancer underscores the need to attract medical students to oncology. Caribbean medical schools play a pivot...
Time to treatment initiation (TTI) in patients with colorectal cancer and liver metastases.
3568 Background: In colorectal cancer (CRC), the liver represents a common site of metastatic disease, and patients with colorectal liver metastases (CRLM...
Clinical responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
2504 Background: Metastatic castration-resistant prostate cancer (mCRPC) has a poor response to immunotherapy limited by both a low ORR and high frequency...
Final results of a phase II study of cabozantinib in patients with <i>MET</i> -altered lung cancers.
8645 Background: MET alterations define a subgroup of non-small cell lung cancers (NSCLC) sensitive to MET tyrosine kinase inhibitors (TKIs)....
Pricing, availability, and affordability of cancer medicines in 5 middle-income countries in South America.
e23154 Background: Whereas cancer rates are increasing globally, access to antineoplastic drugs is limited and expensive, especially in low and middle-inc...
Lorlatinib in TKI-naïve patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from India.
e20679 Background: Lorlatinib is a novel brain penetrant 3rd generation anaplastic lymphoma kinase (ALK)- inhibitor, approved as frontline & subsequen...
Clinical and molecular features of resected breast cancer brain metastases: A retrospective cohort study.
e14013 Background: Brain metastases (BMs) are a significant cause of morbidity and mortality in patients (pts) with metastatic breast cancer (MBC). Some p...
First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors.
2591 Background: Outcomes for patients with epithelial cancers, including breast, lung and gastrointestinal tumors, remain...
The analysis of pathological prognostic factors related to lymphovascular invasion (LVI) and perineural invasion (PNI) in esophageal squamous cell carcinoma.
e16150 Background: To explore the correlation between lymphovascular invasion(LVI)/perineural invasion(PNI) and other clinical features of esophageal squa...
Efficacy and safety of bisphosphonates therapy for patients diagnosed with multiple myeloma: A comprehensive Bayesian network meta-analysis.
e19526 Background: Multiple myeloma (MM) is a hematologic malignancy characterized by clonal plasma cell proliferation in the bone marrow, leading to skel...
Evaluation of de novo oligometastatic, oligorecurrent, and oligoprogressive prostate cancer patients managed with radiation therapy: A multi-institution, real-world dataset.
5099 Background: Oligometastatic prostate cancer (omPCa) is historically defined as ≤5 metastases, with non-standard treatment approaches and unknown prev...
Pregnancy-associated breast cancer: Tumor infiltrating lymphocytes TILting the balance?
564 Background: Pregnancy-Associated Breast Cancer (PABC), which includes breast cancer diagnosed during pregnancy (PrBC) or postpartum (PPBC), is often m...
PUNCH03: A phase II study of disitamab vedotin combined with tislelizumab and bacillus Calmette-Guerin (BCG) in Her2-positive high-risk non-muscle-invasive bladder cancer (HR NMIBC).
TPS4624 Background: Disitamab vedotin (RC48) was a novel antibody drug conjugate that targets the Her2 protein. The KEYNOTE-057 study has supported the be...
Real-world data on pathological complete response and outcomes in hormone-receptor–positive breast cancer: An Indian experience.
e13045 Background: The data on the pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) for hormone receptor-positive breast cancer...
Phase II assessment of carboplatin with etoposide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
10006 Background: rEECur, the first randomised controlled trial (RCT) in RR-ES, has previously defined high dose ifosfamide (IFOS) as the most effective r...
Investigating age of onset and prognosis of p53 mutant myeloid malignancies in African Americans.
6547 Background: TP53 mutations drive poor outcomes in Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), aggressive hematologic malignancie...
Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma.
11531 Background: Chemotherapy remains the cornerstone for treatment of soft tissue sarcomas (STS). Biomarkers are needed to enhance timely assessment of...
Cost-effectiveness of HER2/neu 655 genotyping in managing trastuzumab-induced cardiotoxicity risk in HER2-positive breast cancer patients.
543 Background: Trastuzumab has significantly improved survival in HER2-positive breast cancer patients. However, around 20% of patients experience cardio...
The anti-STEAP1/PSMA ADC, DXC008: Assessment of anti-tumor efficacy, pharmacokinetic, and toxicity properties.
e17161 Background: Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is highly expressed in multiple tumor types, including prostate cancer, Ewi...
STEP-1: A SickKids pilot providing upfront financial support for pediatric and adolescent patients travelling to access academic phase 1-2 studies in Canada.
e13501 Background: Equitable access to early phase trials for all Canadian children with hard-to-cure cancer is crucial. While industry-sponsored studies...